Tong Ren Tang Technologies deputy chairman Wang Zhaoqi says the H share has not thought of shifting its listing to the main board from the Growth Enterprise Market, stagnant since the high-technology bubble burst.
The rapidly expanding company boosted net profit by a year-on-year 70.7 per cent to 65.57 million yuan (about HK$61.43 million) for the nine months to September 30.
Turnover for the Chinese patent medicine manufacturer was up 48 per cent to 364.02 million yuan. Sales on the mainland rose 42 per cent to 340 million yuan, but the growth was dwarfed by the 150 per cent sales rise overseas - to 15.49 million yuan.
The company is looking to diversify into the bio-pharmaceutical business through a joint venture with WM Dianorm Biotech.
It will also study the possibility of selling products in a different form in the United States through a HK$6 million venture with Hutchison Whampoa.
Tong Ren Tang has invested three million yuan in the research and development of products to treat influenza, cardiovascular disease and menopause. Due to the need to raise production to cope with the rising demand it has invested 17.66 million yuan on a factory in the Beijing Economic and Technology Development Zone.
